Aegis Awarded Patent for Interferon Alpha, Beta, and Gamma Formulations That Eliminate Aggregation and Associated Immunogenicity and Are Suitable for Non-Invasive or Injectable Delivery
January 04, 2012 04:00 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - Jan 4, 2012) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,084,022 providing broad protection for stabilized formulations of alpha,...
Aegis Therapeutics Awarded Patent for Parathyroid Hormone (PTH) Peptide Drug Formulations Suitable for Metered Nasal Spray and Oral Delivery
December 13, 2011 00:05 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - Dec 13, 2011) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,076,290, providing broad protection for stabilized formulations of...
Aegis Therapeutics Awarded Patent for GLP-1 Peptide Drug Formulations Suitable for Metered Nasal Spray and Oral Delivery
August 16, 2011 00:05 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - Aug 16, 2011) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 7,998,927 providing broad protection for stabilized formulations of...
Albany Medical College and Aegis Therapeutics Form Partnership to Advance Leading Edge Oral Breast Cancer Drug Candidate Derived From a Natural Pregnancy Associated Protein
May 10, 2011 00:10 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - May 10, 2011) - Scientists at Albany Medical College have developed a potential new breast cancer drug based on a naturally occurring protein of human pregnancy. The drug...
Oral Bioavailability of Octreotide Using Aegis' Intravail(R) Formulation Technology Surpasses That Obtained by Injection
April 13, 2011 12:02 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - Apr 13, 2011) - Scientists at Albany Medical College and Aegis Therapeutics report that oral delivery of the peptide drug octreotide, in the presence of the absorption...
Aegis' ProTek(R) Excipients Prevent Aggregation and Eliminate Unwanted beta-Interferon Immunogenicity
September 01, 2010 00:00 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - September 1, 2010) - Recombinant human beta-interferon reduces the frequency of multiple sclerosis (MS) exacerbations and improves MS outcome measures....
First Orally Bioavailable Anti-Obesity/Diabetes Peptide Drug Candidate to Be Presented at the Endocrine Society Annual Meeting in San Diego, June 19-22, 2010
May 13, 2010 00:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - May 13, 2010) - Data demonstrating the efficacy of the first and only anti-obesity and anti-diabetic peptide drug candidate not requiring injection will be presented...
Aegis Therapeutics and Dr. Reddy's Announce Strategic Alliance
January 25, 2010 00:01 ET
|
Aegis Therapeutics LLC
HYDERABAD, INDIA and SAN DIEGO, CA--(Marketwire - January 25, 2010) - Dr. Reddy's Laboratories
(NYSE: RDY) and Aegis Therapeutics, LLC (Aegis) today announced a
partnership providing Dr. Reddy's...
Aegis Therapeutics and Roche Enter Into a License Agreement for ProTek(R) Stabilization
December 01, 2009 00:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - December 1, 2009) - Aegis Therapeutics LLC (Aegis) announced
today that they have signed a License Agreement providing Roche access to
Aegis' proprietary ProTek®...
Aegis Therapeutics and Phylogica Collaborate to Deliver Phylomer Peptide Drugs With Patient-Friendly Intranasal Sprays
April 14, 2009 00:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - April 14, 2009) - Aegis Therapeutics LLC ("Aegis") and
Australian Drug Discovery company Phylogica Limited (ASX: PYC)
("Phylogica") today announced a collaboration to use...